DICOPAC KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DICOPAC KIT (DICOPAC KIT).
DICOPAC KIT contains C-11 dihydrotetrabenazine (DTBZ), a radioligand that binds to vesicular monoamine transporter 2 (VMAT2) in the brain. It is used for positron emission tomography (PET) imaging to assess VMAT2 density in patients with suspected Parkinsonian syndromes.
| Metabolism | The active moiety, C-11 DTBZ, undergoes rapid metabolism via hepatic O-demethylation and glucuronidation, mediated by CYP2D6 and UGT enzymes. |
| Excretion | Renal: ~30% as unchanged drug; Fecal/biliary: ~70% as metabolites. Complete renal elimination of radioactivity within 72 hours. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours in normal renal function. May be prolonged in renal impairment. |
| Protein binding | ~90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.5 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Subcutaneous: 100% (administered as solution). Not administered orally. |
| Onset of Action | Subcutaneous injection: Time to peak plasma concentration is 2-4 hours. Clinical effect onset not applicable as diagnostic agent. |
| Duration of Action | Duration of diagnostic imaging window is typically 30-60 minutes post-injection. No therapeutic duration. |
DICOPAC KIT is not a drug but a radiopharmaceutical diagnostic agent. Standard adult dose: 4 mCi (148 MBq) of Technetium-99m pertechnetate, administered as a single intravenous injection.
| Dosage form | N/A |
| Renal impairment | No dose adjustment is required for renal impairment as the tracer is excreted via the renal system; however, in severe renal failure (GFR <30 mL/min), image quality may be suboptimal due to reduced renal uptake. |
| Liver impairment | No dose adjustment is necessary for hepatic impairment; however, severe hepatic dysfunction may alter biodistribution and image quality. |
| Pediatric use | Pediatric dose is weight-based: 0.1 mCi/kg (3.7 MBq/kg) with a minimum of 1 mCi (37 MBq) and maximum of 4 mCi (148 MBq). Administer intravenously. |
| Geriatric use | No specific dose adjustment is required for geriatric patients; however, age-related renal decline may affect image clearance. Use the standard adult dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DICOPAC KIT (DICOPAC KIT).
| Breastfeeding | Breastfeeding is contraindicated during and for 24-48 hours after administration due to excretion of radioactivity into breast milk. M/P ratio is not established for diphosphonate compounds; however, technetium-99m has a short physical half-life (6 hours). Interruption of breastfeeding is recommended; pump and discard milk for at least 24 hours. |
| Teratogenic Risk | DICOPAC KIT contains technetium-99m coupled to diphosphonate compounds. Radiopharmaceuticals pose a teratogenic risk due to ionizing radiation exposure. First trimester: High risk of congenital anomalies; contraindicated unless essential. Second and third trimesters: Risk of fetal growth restriction and potential neurodevelopmental effects; use only if benefit justifies risk. Fetal dose should be minimized. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to dihydrotetrabenazine or any component of the formulation.","Pregnancy: Use only if benefits outweigh risks due to radiation exposure.","Lactation: Discontinue breastfeeding temporarily after administration to minimize infant radiation exposure."]
| Precautions | ["Radiation risk: The product emits ionizing radiation, which may increase the risk of cancer, especially in children and young adults.","Allergic reactions: Rare hypersensitivity reactions may occur.","Interpretation limitations: PET imaging results should be considered in conjunction with clinical findings."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during administration. No specific fetal monitoring is required, but limit fetal radiation exposure by using lowest possible dose and ensuring adequate hydration to promote excretion. Post-procedure, confirm absence of extravasation. |
| Fertility Effects | High doses of radiopharmaceuticals may cause temporary or permanent gonadal damage, affecting fertility. Technetium-99m diphosphonate at diagnostic doses is unlikely to cause permanent fertility impairment, but repeated exposure or higher doses may increase risk. Counsel patients planning pregnancy to delay imaging until after conception or use alternative imaging. |